Clinical trials: Tumor Pancreas
Pancreas Ductal Adenocarcinoma
Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer
Based on the superior efficacy and safety profile of liposomal irinotecan over irinotecan in pancreatic cancer, as well as preliminary results from earlier studies evaluating nab-paclitaxel and gemcitabine (AG) combined with…
- Trial name
- NCT07806110
- Testing
- SHR-1701, liposomal irinotecan+nab-paclitaxel+gemcitabine
- Where
- China
- Volunteers
- 62 people
- Sponsor
- The First Hospital of Jilin University
Pancreatic Cancer
Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer
This study will examine an investigational (experimental) treatment using gemcitabine, cisplatin, and celecoxib. Preliminary studies have shown that this experimental treatment may be effective in reducing the size of cancerous…
- Trial name
- NCT00176813
- Testing
- Gemcitabine, Cisplatin, Celecoxib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan Rogel Cancer Center
Malignant Biliary Obstruction, Advanced Pancreatic Cancer and Cholangiocarcinoma
Improving a Bile Duct Drainage Procedure in Patients With Inoperable Cancer Blocking the Bile Ducts: Comparing Two Types of Endoscopically Placed Internal Stents to Prevent Blockage of a Lumen Apposing Metal Stent
This study looks at the best way to treat bile duct blockage in people with advanced cancer that cannot be removed by surgery. A blocked bile duct can cause serious symptoms like yellowing of the skin (jaundice), infection, and…
- Conditions
- Malignant Biliary Obstruction, Advanced Pancreatic Cancer and Cholangiocarcinoma, Inoperable Malignant Biliary Obstruction, Lumen Apposing Metal Stents
- Trial name
- Opti-LAMS (NCT07115420)
- Testing
- Fully covered self expanding metal stent (FCSEMS) within LAMS, Double pigtail stent (DPS) within LAMS
- Where
- New Zealand
- Volunteers
- 100 people
- Sponsor
- Waikato Hospital
Pancreatic Cancer
Preoperative Exercise in Pancreatic Cancer
The purpose of this study is to investigate the effects of a preoperative exercise program in patients with pancreatic cancer preparing for surgery.
- Trial name
- NCT02648880
- Testing
- Exercise program, Standard Care
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Colorado, Denver
Pancreatic Adenocarcinoma Resectable
A Pilot Study of IRE for Resectable Pancreatic Cancer
The operation to remove certain pancreatic cancers (Whipple procedure), even in 2017, remains one of the most complicated surgeries done in the abdomen.
- Trial name
- NCT03337997
- Testing
- Irreversible Electroporation
- Where
- Canada
- Sponsor
- University of Saskatchewan
Pancreatic Neuroendocrine Tumor
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
This research study will test the safety of RAD001 in combination with temozolomide.
- Trial name
- NCT00576680
- Testing
- RAD001, Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Solid Tumors, Glioblastoma
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.
- Conditions
- Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma
- Trial name
- NCT02611024
- Testing
- Lurbinectedin, Irinotecan
- Where
- 23 sites in United States, France and 4 more
- Volunteers
- 316 people
- Sponsor
- PharmaMar
Lung Cancer, Liver Cancer
The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy
This is a clinical study focused on the use of fiducial marker-guided stereotactic body radiotherapy (SBRT) for treating malignant tumors, including lung, liver, pancreatic, and kidney/adrenal cancers.
- Conditions
- Lung Cancer, Liver Cancer, Pancreatic Cancer, Renal Cell Carcinoma
- Trial name
- ONFM-SBRT (NCT06342323)
- Testing
- SBRT
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Peking University Third Hospital
Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer, Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer
Optional Sub-study to Intraoperative Imaging With ICG Registry
The primary goal of this optional sub-study is to record what tissues fluoresce in the operating room, and then to identify if these lesions are cancer when the histopathology is performed.
- Conditions
- Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer, Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer, Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer
- Trial name
- NCT02651246
- Testing
- data collection
- Where
- United States
- Volunteers
- 291 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Advanced Pancreatic Cancer
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
This trial is the cohort C part of a multicenter, open label Phase Ib/II clinical study evaluating the preliminary efficacy, safety, and tolerability of LM-108 combined with anti-tumor therapy in patients with advanced solid…
- Trial name
- NCT06821503
- Testing
- LM-108 injection, Penpulimab injection, Paclitaxel for injection (albumin bound)
- Where
- 16 sites in China
- Volunteers
- 72 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gastrointestinal Cancer, Pancreatic Cancer
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Background: A new cancer therapy takes white blood cells from a person, grows them in a lab, genetically changes them, then gives them back to the person.
- Conditions
- Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer
- Trial name
- NCT03745326
- Testing
- Cyclophosphamide, Fludarabine, Aldesleukin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Dasatinib in Treating Patients With Stage IV Pancreatic Cancer
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with stage IV pancreatic…
- Trial name
- NCT00544908
- Testing
- dasatinib, immunoenzyme technique, immunohistochemistry staining method
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Unresectable Pancreatic Cancer
Bioinformation Therapy for Pancreatic Cancer
The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable pancreatic cancer.
- Trial name
- NCT03239184
- Testing
- Cancer ablation, Life information rehabilitation therapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Stage IV Pancreatic Cancer
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
The Investigators in the PCRT team have developed a therapeutic regimen which attacks both the tumor compartment and the stromal compartment of pancreatic cancer and induces complete responses in a small percentage of patients…
- Trial name
- NCT01488552
- Testing
- Gemcitabine, nab-paclitaxel, FOLFIRINOX
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pancreatic Cancer Research Team
Metastatic Pancreatic Cancer
Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients
This randomized, Phase 2, open label study aims to assess the efficacy and safety of gemcitabine + nab paclitaxel with or without dociparstat (ODSH) as first line treatment of metastatic pancreatic cancer.
- Trial name
- PGPC1 (NCT01461915)
- Testing
- Nab paclitaxel, Gemcitabine, Dociparstat
- Where
- 16 sites in United States
- Volunteers
- 60 people
- Sponsor
- Jazz Pharmaceuticals
Pancreatic Cancer
Pancreatic Adenocarcinoma Gene Environment Risk Study
After informed consent, participants will be asked to complete a medical/family history questionnaire and provide a blood sample. Some participants may also be asked to provide a urine sample.
- Trial name
- PAGER (NCT00912717)
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
This phase II trial is studying how well saracatinib works in treating patients with previously treated metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT00735917
- Testing
- saracatinib, pharmacogenomic studies, pharmacological study
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors, Neoplasms (Cancer / Tumors)
Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor
The goal of this clinical trial is to learn if Trastuzumab Rezetecan can treat advanced solid tumors with HER-2 expression in adult participants.
- Conditions
- Solid Tumors, Neoplasms (Cancer / Tumors), Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm
- Trial name
- NCT07631884
- Testing
- Trastuzumab Rezetecan
- Volunteers
- 15 people
- Sponsor
- Haihua Yuan
Pancreatic Ductal Carcinoma
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with…
- Trial name
- NCT02715804
- Testing
- Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20), nab-Paclitaxel, Gemcitabine
- Where
- 217 sites in United States, Australia and 20 more
- Volunteers
- 492 people
- Sponsor
- Halozyme Therapeutics
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
This phase I/II trial studies the effect of sonoporation in addition to standard of care chemotherapy in treating patients with pancreatic cancer.
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8
- Trial name
- NCT04821284
- Testing
- Gemcitabine Hydrochloride, Nab-paclitaxel, Fluorouracil
- Where
- 2 sites in United States, Norway
- Volunteers
- 120 people
- Sponsor
- Flemming Forsberg
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.